Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.18 -0.56 (-1.15%)
Streaming Delayed Price Updated: 12:19 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
News headline image
Why Scholar Rock Shares Are Soaring Today ↗
Via The Motley Fool
Topics Stocks
News headline image
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies ↗
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
News headline image
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
News headline image
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Why Novo Nordisk Stock Sank by Nearly 4% Today ↗
Via The Motley Fool
News headline image
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗
A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic. 
Via Benzinga
Topics Intellectual Property
News headline image
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
News headline image
3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗
Via The Motley Fool
News headline image
1 Growth Stock Down 9% to Buy Right Now ↗
Via The Motley Fool
News headline image
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company ↗
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Why Novo Nordisk Stock Pumped Higher on Thursday ↗
Via The Motley Fool
News headline image
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking ↗
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills ↗
Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows. 
Via Benzinga
News headline image
4 Dividend Stocks to Double Up on Right Now ↗
The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock? ↗
Via The Motley Fool
News headline image
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice ↗
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned. 
Via Benzinga
News headline image
Nvidia Extends AI Reach In Europe With Alliances ↗
Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels ↗
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies ↗
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity. 
Via Benzinga
News headline image
Why Novo Nordisk Stock Just Popped ↗
Novo Nordisk stock has multiple catalysts that could soon reverse is slide. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
2 Weight Loss Drug Stocks That Are Screaming Buys in June ↗
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings. 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Eked Out a Win on Monday ↗
Via The Motley Fool
News headline image
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch ↗
The company is planning to soon begin combination studies, testing two of its drugs in weight loss. 
Via Investor's Business Daily
Topics Bankruptcy
News headline image
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy ↗
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
News headline image
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? ↗
Via The Motley Fool
Topics Supply Chain
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS